Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Unveiling the Secrets of IL-17A Inhibitors: Stay Updated with the Latest Advances
Valuable Targets
4 min read
Unveiling the Secrets of IL-17A Inhibitors: Stay Updated with the Latest Advances
29 November 2023
IL-17A inhibitors are a class of drugs that target the cytokine IL-17A, playing a crucial role in treating inflammation and autoimmune diseases.
Read →
Initial Participant Registered for the Phase 1 Investigation of MRX-5
Latest Hotspot
3 min read
Initial Participant Registered for the Phase 1 Investigation of MRX-5
29 November 2023
Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. revealed that the first volunteer has been enlisted for the initial Phase I clinical examination of its innovative antibiotic MRX-5 in Australia.
Read →
Ruxolitinib Phosphate: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ASH
Clinical Progress
6 min read
Ruxolitinib Phosphate: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ASH
29 November 2023
On 10 Dec 2023, the 3-Year final analysis of efficacy and safety of Ruxolitinib from the phase III REACH3 study will be unveiled at the 2023 ASH Congress.
Read →
Origen Chengdu and Vanotech announce first patient treated with VAN-2201 gene therapy in Phase 1 trial for age-related Wet Macular Degeneration
Latest Hotspot
3 min read
Origen Chengdu and Vanotech announce first patient treated with VAN-2201 gene therapy in Phase 1 trial for age-related Wet Macular Degeneration
29 November 2023
Origen Chengdu and Vanotech have declared the first patient has received their gene therapy in the Phase 1 trial of VAN-2201 for Wet Macular Degeneration associated with aging.
Read →
What are IRAK4 inhibitors and how do you quickly get the latest development progress?
Valuable Targets
4 min read
What are IRAK4 inhibitors and how do you quickly get the latest development progress?
29 November 2023
IRAK4 inhibitors: Pioneering immune response regulation and promising future in combating hematologic malignancies.
Read →
At the 2023 SNO Conference, Imvax showcased new data supporting its main project, IGV-001, for newly discovered Glioblastoma
Latest Hotspot
3 min read
At the 2023 SNO Conference, Imvax showcased new data supporting its main project, IGV-001, for newly discovered Glioblastoma
29 November 2023
At the 2023 SNO Annual Conference, Imvax displayed novel findings advocating for its principal project, IGV-001, targeting recently identified Glioblastoma.
Read →
An analysis of UCART-22's R&D progress and its clinical results presented at the 2023 ASH Annual Meeting
Clinical Progress
5 min read
An analysis of UCART-22's R&D progress and its clinical results presented at the 2023 ASH Annual Meeting
29 November 2023
On 11 Dec 2023, the updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2) in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) will be reported in 2023 ASH.
Read →
HOOKIPA Pharma reveals FDA's approval for their new investigative drug, HB-500, to treat HIV
Latest Hotspot
3 min read
HOOKIPA Pharma reveals FDA's approval for their new investigative drug, HB-500, to treat HIV
29 November 2023
HOOKIPA Pharma Inc. has officially disclosed that the FDA has given the clearance for its IND application for HB-500, This is a new arenaviral therapeutic vaccine designed for HIV treatment.
Read →
Unveiling the Secrets of JAK2 Inhibitors: Stay Updated with the Latest Advances?
Valuable Targets
4 min read
Unveiling the Secrets of JAK2 Inhibitors: Stay Updated with the Latest Advances?
29 November 2023
JAK2 inhibitors: Revolutionizing treatments for hematological disorders with a promising future.
Read →
Sandoz introduces Hyrimoz® (adalimumab) high-dose variant in Europe to enhance patient treatment
Latest Hotspot
3 min read
Sandoz introduces Hyrimoz® (adalimumab) high-dose variant in Europe to enhance patient treatment
29 November 2023
Sandoz announces the launch of its citrate-free high concentration Hyrimoz® (adalimumab) in Europe, with availability starting today in various countries.
Read →
Decoding Axicabtagene Ciloleucel: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
Clinical Progress
6 min read
Decoding Axicabtagene Ciloleucel: a comprehensive study of its R&D trends and its clinical results in 2023 ASH
29 November 2023
On 11 Dec 2023, The clinical data about Axicabtagene Ciloleucel from pivotal ZUMA-7 study will be updated in 2023 ASH.
Read →
European Commission approves Ascendis Pharma's YORVIPATH® (palopegteriparatide) for treating chronic Hypoparathyroidism in adults
Latest Hotspot
3 min read
European Commission approves Ascendis Pharma's YORVIPATH® (palopegteriparatide) for treating chronic Hypoparathyroidism in adults
29 November 2023
European Commission gives the green light to Ascendis Pharma's YORVIPATH® (palopegteriparatide) for managing chronic Hypoparathyroidism in adults.
Read →